Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels

Author:

Wiedmann Felix123,Schlund Daniel12,Kraft Manuel123,Nietfeld Jendrik12,Katus Hugo A123,Schmidt Constanze123,Thomas Dierk123

Affiliation:

1. Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

2. HCR (Heidelberg Center for Heart Rhythm Disorders), University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

3. DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

Abstract

Abstract Aims  Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The efficacy of NOACs has been attributed in part to pleiotropic effects that are mediated through effects on thrombin, factor Xa, and their respective receptors. Direct pharmacological effects of NOACs and cardiac ion channels have not been addressed to date. We hypothesized that the favourable clinical outcome of NOAC use may be associated with previously unrecognized effects on atrial repolarizing potassium channels. Methods and results  This study was designed to elucidate acute pharmacological effects of NOACs on cloned ion channels Kv11.1, Kv1.5, Kv4.3, Kir2.1, Kir2.2, and K2P2.1 contributing to IKr, IKur, Ito, IK1, and IK2P K+ currents. Human genes, KCNH2, KCNA5, KCND3, KCNJ2, KCNJ12, and KCNK2, were heterologously expressed in Xenopus laevis oocytes, and currents were recorded using voltage-clamp electrophysiology. Apixaban, dabigatran, edoxaban, and rivaroxaban applied at 1 µM did not significantly affect peak current amplitudes of Kv11.1, Kv1.5, Kv4.3, Kir2.1, Kir2.2, or K2P2.1 K+ channels. Furthermore, biophysical characterization did not reveal significant effects of NOACs on current–voltage relationships of study channels. Conclusion  Apixaban, dabigatran, edoxaban, and rivaroxaban did not exhibit direct functional interactions with human atrial K+ channels underlying IKr, IKur, Ito, IK1, and IK2P currents that could account for beneficial clinical outcome associated with the drugs. Indirect or chronic effects and potential underlying signalling mechanisms remain to be investigated.

Funder

University of Heidelberg

Rahel Goitein-Straus Scholarship and Olympia-Morata Scholarship

DZHK

German Center for Cardiovascular Research

Joachim-Herz Foundation

German Cardiac Society

Research Scholarship

German Heart Foundation

German Foundation of Heart Research

Joachim Siebeneicher Foundation

Deutsche Forschungsgemeinschaft

German Research Foundation

Ministry of Science, Research and the Arts Baden-Wuerttemberg

Else-Kröner Fresenius Foundation

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference15 articles.

1. The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation;Schmidt;Vasc Health Risk Manag,2011

2. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

3. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N Engl J Med,2011

4. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

5. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med,2013

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3